(PR-inside.com) Research and Markets (http://www.researchandmarkets.com/re...orectal_cancer) has announced the addition of the 'Colorectal Cancer Drug Pipeline Update 2009' report to their offering. Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years. There are today more than 270 therapeutics targeting colorectal cancer in active development, from early preclinical to marketed ..
More...
More...